Process Optimization Of the Medicines’ pAthway in nursing Homes

Evaluation and comparison of the effectiveness of four different support programs (from access to a toolbox to the integration of a coordinating pharmacist) on the quality of the medicines’ pathway in nursing homes

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN17231220

Enrollment

100

Registered

2025-05-07

Start date

2024-03-11

Completion date

Unknown

Last updated

2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Improvement of the quality of the medicines' pathway in nursing homes Other

Interventions

Nursing homes (NHs) are allocated to one of the four support programs, receiving different formats and intensities of support during one year (2025). NHs in Program 1 gain access to a (mostly digita

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Local project teams: at least the nursing home's coordinating physician, quality coordinator and one head nurse 2. Other nursing home staff: nurses, nurse aids, pharmacist, general practitioners, ... - if involved or targeted by the quality improvement initiatives set up by the nursing home 3. Nursing home residents and carers - if involved or targeted by the quality improvement initiatives set up by the nursing home

Exclusion criteria

Exclusion criteria: 1. Short stay, service flats, or revalidation 2. Refusal to participate

Design outcomes

Primary

Measure	Time frame
The primary outcome consists of the quality of the medicines’ pathway in participating NHs. This quality is represented by overall performance scores which are calculated through performance questionnaires, measured both at baseline (end of 2024) at the end of the study (i.e. after 1 year, January 2026).	—

Secondary

Measure	Time frame
1. Number of (psychoactive) medications used by residents, reported in an Excel-file by each nursing home, both at baseline (end of 2024) at the end of the study (i.e. after 1 year, January 2026). 2. Quality of individual processes of the medicines’ pathway, represented by process-specific performance scores that are calculated through performance questionnaires, measured both at baseline (end of 2024) at the end of the study (i.e. after 1 year, January 2026). 3. Quality of important key activities of the medicines’ pathway, represented by activity-specific performance scores that are calculated through performance questionnaires, measured both at baseline (end of 2024) at the end of the study (i.e. after 1 year, January 2026). 4. Number of falls of residents, reported in an Excel-file by each nursing home, both at baseline (end of 2024) at the end of the study (i.e. after 1 year, January 2026). 5. Number of hospitalizations of residents, reported in an Excel-file by each nursing home, both at baseline (end of 2024) at the end of the study (i.e. after 1 year, January 2026).	—

Measure

Time frame

1. Number of (psychoactive) medications used by residents, reported in an Excel-file by each nursing home, both at baseline (end of 2024) at the end of the study (i.e. after 1 year, January 2026). 2. Quality of individual processes of the medicines’ pathway, represented by process-specific performance scores that are calculated through performance questionnaires, measured both at baseline (end of 2024) at the end of the study (i.e. after 1 year, January 2026). 3. Quality of important key activities of the medicines’ pathway, represented by activity-specific performance scores that are calculated through performance questionnaires, measured both at baseline (end of 2024) at the end of the study (i.e. after 1 year, January 2026). 4. Number of falls of residents, reported in an Excel-file by each nursing home, both at baseline (end of 2024) at the end of the study (i.e. after 1 year, January 2026). 5. Number of hospitalizations of residents, reported in an Excel-file by each nursing home, both at baseline (end of 2024) at the end of the study (i.e. after 1 year, January 2026).

—

Countries

Belgium

Contacts

Public ContactAmber;Astrid Damiaens;Frisson

;

amber.damiaens@kuleuven.be;astrid.frisson@kuleuven.be+32 16 19 41 74 ;+32 16 32 25 65

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026